As of June 30, 2026, Rocket Pharmaceuticals, Inc. carries a market capitalization of 325.33M, placing it among publicly traded companies globally. Its enterprise value stands at 98.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 325.33M |
| Enterprise Value | 98.67M |
Rocket Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 1, 2027.
| Earnings Date | 3/1/2027 |
As of June 30, 2026, Rocket Pharmaceuticals, Inc. has 109.54M shares outstanding.
| Shares Outstanding | 109.54M |
These figures are as of June 30, 2026.
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | -2.24 |
| P/OCF Ratio | -2.23 |
As of June 30, 2026, Rocket Pharmaceuticals, Inc. maintains a current ratio of 9.24, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.72, indicating elevated leverage, while an interest coverage ratio of -96.16 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.24 |
| Quick Ratio | 9.06 |
| Debt / Equity | 6.72 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | -96.16 |
Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -4.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.09, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 226.25, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -4.77 |
| Return on Assets (ROA) | -4.09 |
| Employee Count | 226.25 |
Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. recorded 7.55M in income tax expense. The company reported a pretax loss of -7.55M and -15.10M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 7.55M |
As of the close on November 17, 2026, Rocket Pharmaceuticals, Inc.'s stock has declined approximately 24.14% over the past 52 weeks. The 50-day moving average sits at 2.35, while the 200-day moving average is 2.93.
| 52-Week Price Change | -24.14% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 2.93 |
Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. generated - - in revenue and converted that into -15.10M in net income, yielding earnings per share of -0.13. EBITDA reached -159.25M, while operating income came in at -167.96M.
| Operating Income | -167.96M |
| Pretax Income | -7.55M |
| Net Income | -15.10M |
| EBITDA | -159.25M |
| EBIT | -167.75M |
| Earnings Per Share (EPS) | -0.13 |
As of June 30, 2026, Rocket Pharmaceuticals, Inc. holds 248.36M in cash and equivalents against 21.71M in total debt, resulting in a net debt position of -196.51M. Total book value stands at 322.84M, with working capital of 226.03M providing operational flexibility.
| Cash & Cash Equivalents | 248.36M |
| Total Debt | 21.71M |
| Net Debt | -196.51M |
| Equity (Book Value) | 322.84M |
| Book Value Per Share | 2.95 |
| Working Capital | 226.03M |
Rocket Pharmaceuticals, Inc. produced -149.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -111,163.10 in capital expenditures, free cash flow totaled -149.15M - equivalent to -1.33 per share.
| Operating Cash Flow | -149.03M |
| Capital Expenditures | -111,163.10 |
| Free Cash Flow | -149.15M |
| FCF Per Share | -1.33 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.02, meaning Rocket Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.02 |
| FCF Yield | -44.64 |
Rocket Pharmaceuticals, Inc.'s most recent stock split took place on January 5, 2018 with a 4:1 split ratio.
| Last Split Date | 1/5/2018 |
| Split Ratio | 4:1 |
As of June 30, 2026, Rocket Pharmaceuticals, Inc. has an Altman Z-Score of -2.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.12 |